QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.107.043372v1 73/6/1679    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Serra, J. M. Articles by Besalduch, J. Search for Related Content PubMed PubMed Citation Articles by Serra, J. M. Articles by Besalduch, J.

Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

Department of Hematology, Institut Universitari d'Investigacions en Ciències de la Salut (IUNICS) (J.M.S., A.G., M.N., A.S., J.C.A., A.G., J.B) and Departments of Pathology (C.S.), Pharmacy (J.G.), and Oncology (J.M), University Hospital Son Dureta, Palma de Mallorca, Spain; and Group of Clinical and Molecular Onco-Hematology, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain (J.M.S., A.G., R.A., T.R., L. S.-M., J.M., O.V.)

Non-small-cell lung cancer (NSCLC) is characterized by severe resistance to chemotherapy. Here, we demonstrate that A549 adenocarcinoma cells permanently differentiate with the antimetabolites methotrexate (MTX) and gemcitabine (GE) when blocking the resistance mechanism that normally counteracts this process. MTX (1-10 µM) and GE (1 µM) induced growth arrest accompanied by sustained extracellular signal-regulated kinase (ERK1/2) phosphorylation and moderate reduction of c-Myc levels after 96 h, whereas only a low percentage of the cells differentiated. Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells. Besides the appearance of multilamellar bodies and intracellular cytokeratin reorganization, modulation of molecular markers occurred in a manner consistent with differentiation (gelsolin, +300%; surfactant protein A and C, -70%). Similar to U0126, c-Myc inactivation with specific small interfering RNA initiated differentiation only in the presence of MTX, demonstrating that inhibition of the mitogen-activated protein kinase/ERK pathway alone or down-regulation of c-Myc is not sufficient to induce this process. It is noteworthy that withdrawal of antitumoral drugs and U0126 neither reversed differentiation nor reactivated proliferation. Our results reveal that maintenance of a certain threshold of c-Myc expression through sustained ERK1/2 activation represents a molecular mechanism that confers resistance to antimetabolite-induced differentiation in A549 cells, and provide a novel molecular basis for therapeutic strategies based on irreversible differentiation of cancer cells using conventional chemotherapeutic antimetabolites in combination with inhibitors of the MEK/ERK pathway or c-Myc.

Address correspondence to: Jordi M. Serra, Department of Hematology, Institut Universitari d'Investigacions en Ciències de la Salut (IUNICS), University Hospital Son Dureta, c/Andrea Dòria 55, E-07014 Palma de Mallorca, Spain. E-mail: jmserra{at}hsd.es